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  Abstract 
  Polycomb group (PcG) proteins are important to the regulation of hematopoiesis by regulating 
chromatin compaction and silencing genes related to differentiation and cell cycle. The 
overexpression of Ezh2 and Bmi-1/PCGF4, has been implicated in solid organ cancers. Meanwhile, 
Mel-18/PCGF2 was reported as a tumor suppressor. The detailed expression profiles of PcG 
proteins and diagnostic significance in malignant lymphomas are still unknown. In this study, we 
analyzed the expression levels of Ezh2, Bmi-1, Mel-18 and Ki67 in 197 Hodgkin’s and non-
Hodgkin’s lymphoma patient samples and in lymphoma cell lines using immunohistochemical, 
fluorescent immunocytochemical and Western blotting.  Immunohistochemical staining showed 
that Ezh2 expression was significantly increased in aggressive compared to indolent subtypes of B-
cell neoplasms (P=0.000~0.030) while no significant differences were found in Bmi-1 expression 
among these subtypes. Compared to the normal counterpart, T-cell lymphomas showed significant 
overexpression of Bmi-1 (P=0.011) and Ezh2 (P=0.000). The Ki67 labeling index showed a 
positive correlation with Ezh2 in B-cell lymphomas (correlation coefficient: Co=0.983, P=0.000) 
and T/NK- cell lymphomas (Co=0.629, P=0.000). Fluorescent immunohistochemical staining 
showed co-expression of Ezh2 and Ki67 in the same tumor cells, indicating that Ezh2 expression 
correlates with cell proliferation. Both B-and T/NK cell neoplasms showed low expression of Mel-
18 and high expression of both Bmi-1 and Ezh2. In conclusion, lymphomas show high expression 
of Ezh2 in the aggressive variants, and a dominance of polycomb repressive complex PRC1.4 over 
PRC1.2. Coexpression of Bmi-1 and Ezh2 is a characteristic of aggressive lymphomas. Ezh2 
correlates with the proliferation and aggressive nature of non-Hodgkin’s lymphomas. 
 
Keywords: Ezh2, Bmi-1, Mel-18, malignant lymphoma, PRC1.2, PRC1.4 
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Introduction 
Non-Hodgkin’s lymphomas show a wide spectrum of morphology and variability in 
prognosis between different subtypes. Genetic abnormalities are not enough to explain the entire 
multi-step lymphomagenesis process. Aberrant epigenetic changes, including DNA methylation, 
histone modifications, chromatin remodeling and non-coding RNAs (ncRNAs) also contribute to the 
development and progression of malignancy [1-3]. 
Polycomb group (PcG) proteins are important regulators of lymphopoiesis that suppress gene 
expression through epigenetic modifications [4]. They form large multimeric complexes known as 
Polycomb repressive complexes (PRCs), which bind to chromatin and control histone modifications.
 
In mammals, there are two main PcG complexes: Polycomb repressive complexes (PRC1) and 2 
(PRC2). PRC2 includes Enhancer of zeste homologue 2 (Ezh2), Eed, Suz12, RBBP4/7 and Jarid2 [5]. 
PRC1 complexes include several complexes that differ in their localization and function. So far, six 
subgroups have been identified and numbered (PRC1.1~1.6). All of them contain RING1 A and 
RING1 B enzymes, which ubiquitinate histone H2A at the lysine 119 residue [6].  Ezh2 is a histone3 
lysine27 methyltransferase that generates H3K27me3, which is reported to be the binding site of 
PRC1, resulting in the ubiquitination of histones [7, 8]. This association with H3K27me3 was recently 
proven to be specific to PRC1.2 and PRC1.4 [6]. The interaction between PRC1 and PRC2 facilitates 
chromatin compaction, silencing of important tumor suppressors and genes involved in development, 
differentiation, adhesion, cell cycle progression and proliferation. Both groups are important 
developmental regulators in both stem and cancer cells that help control the cell cycle, 
immortalization and self-renewal of normal stem/progenitor cells [4, 9-11].  
Bmi-1/PCGF4 is a component of the PRC1.4 complex, and was described as a proto-
oncogene that induced lymphomas in mice. The upregulation of Bmi-1 was reported in a variety of 
cancers, and sometimes correlated with a poor prognosis [6, 12-14]. Mel-18/PCGF2 is a component 
of the PRC1.2 complex, and was previously described as a tumor suppressor that is expressed in the 
normal state and suppressed in neoplastic conditions in gastric, prostate and breast cancers [15-17].  
PRC1.2 and PRC1.4 complexes are formed, one with canonical PcG components (CBXs, PHCs and 
SCMs) and one with RYBP or YAF2, in addition to Bmi-1/PCGF4 or Mel-18/PCGF2 [6]. 
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Ezh2 overexpression has been reported in solid organ cancers, including breast, prostate and 
stomach cancer. It is associated with metastasis, poor prognosis and treatment failure [18-20]. Somatic 
gain of function mutations in the SET domain of Ezh2, which result in increased histone methylation 
levels, were reported in follicular lymphomas (FL) and diffuse large B cell lymphoma (DLBCL). This 
is in contrast to the loss-of-function mutations reported in patients with myeloid malignancies, most 
commonly in those with myelodysplastic/myeloproliferative neoplasms and myelofibrosis [21-23]. 
However, a lot remains unknown about the expression profiles of PcG proteins and their significance 
in terms of the pathology of lymphoma, especially in T/NK-cell lymphomas. This study investigated 
the expression patterns of Bmi-1, Ezh2 and Mel-18 in different subtypes of B- and T/NK-cell 
neoplasms, and examined the possible correlation with Ki67 expression, as a marker of tumor 
proliferation.  
 
Materials and Methods 
Patient samples 
 Paraffin blocks of 197 lymphoma samples from the archives of the Department of Pathology, 
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University were used 
for the present analyses. The demographic data of the patients and the locations of the neoplasms are 
summarized in Supplemental Table S1.  Reactive lymphoid hyperplasia (RLH, 8 specimens), tonsil (5 
specimens), inflammatory non-neoplastic skin lesions (4 specimens) and thymus (2 specimens) were 
used as normal controls. Informed consent was obtained from all patients for the analysis of their 
tissue samples. This study was approved by the Institutional Review Board of the Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences, Okayama University and related hospitals, in 
accordance with the Declaration of Helsinki. The classification of the neoplasms was done according 
to the REAL/WHO classification.  DLBCL cases were further divided into two groups, germinal 
center type (DLBCL-GCB) and non-germinal center type (DLBCL non-GCB), according to the Hans 
algorithm [24, 25]. 
 
Cell culture 
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The cell lines and culture conditions are summarized in Supplemental Table S2. Peripheral 
blood mononuclear cells (PBMCs) and CD4
+
 T-cells from healthy donors were used as normal 
controls. Immunomagnetic isolation was done using EasySep® Human CD4
+ 
T-Cell Enrichment Kit 
(#19052, Stemcell Technologies, Vancouver, BC, Canada). The Dynabeads® human T-cell activator 
CD3/CD28 was used to activate and expand human T-cells (Invitrogen, Oregon, USA). 
 
Immunohistochemical staining 
Paraffin blocks were retrieved, and new sections were used to ensure the quality of staining. 
Cases in which paraffin blocks were not available to make new sections were excluded. The following 
mouse monoclonal antibodies were used: Ezh2 (clone M18) [26, 27], Bmi-1 (Abcam, MA, USA), 
CD34 (Abcam, MA, USA), CD3 and CD20 (Novocastra, Newcastle upon Tyne, UK), CD56, MUM-1 
(Novocastra, Newcastle upon Tyne, UK), CD4, CD8 (Nichirei Biosciences Inc., Tokyo Japan), CD10, 
CD68, CD138, (Dako, Glostrup, Denmark), BCL6 (Santa Cruz Biotechnologies Inc., Texas, USA), 
rabbit anti-Mel-18 (Santa Cruz Biotechnologies Inc., Texas, USA) and anti-Ki67 (Novocastra, 
Newcastle upon Tyne, UK). Staining was done with a Leica BOND-MAX™ autostainer (Leica 
Biosysytems, Melbourne, Vic., Australia). Both the intensity of staining and percentage of positive 
tumor cells were evaluated in 10 high-power fields by three investigators. A high Ki67 labeling index 
was defined as nuclear staining of ≥ 20% of tumor cells. Positivity was defined as ≥ 25% nuclear 
staining of tumor cells, in accordance with previous reports [14, 20].  Positive cases were further 
scored as (+), (++) and (+++) based on the intensity of the staining, which was judged by comparing it 
to internal control cells. Endothelial cells or adjacent normal/reactive lymphoid tissue served as an 
internal control for Bmi-1. For Ezh2, an adjacent germinal center in nodal and duodenal specimens, or 
the basal epithelial layer in the case of skin and mucous membrane specimens, was used as the 
internal control. For Mel-18, endothelial cells were used as the internal control. A control slide of 
either RLH or tonsil was also included in each staining run. For every case, the neoplastic nature of 
the stained cells was confirmed by its morphology and by using a selection from a panel of markers 
(including CD20, CD138, CD10, CD3, CD4, CD7, CD8, CD56, Cyclin-D1 and BCL2). A 
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combination of each marker (Ezh2, Bmi-1 or Ki67) with B- and T/NK cell markers (CD20, CD3, 
CD56, CD138) was done in normal lymphoid tissue and selected cases of lymphoma.  
 
Double fluorescent immunocytochemical and immunohistochemical staining       
The cells were washed with PBS then processed via cytospin (10
5 
per slide) and fixed in cold 
acetone. Blocking was done by incubation in 5% skim milk for five hours at room temperature. After 
washing, the cells were treated with a mixture of two primary antibodies for three to five hours at 
room temperature. Washing was repeated, then samples were incubated with a mixture of anti-mouse 
and anti-rabbit-IgG for two to three hours at room temperature. The primary antibodies included 
rabbit monoclonal anti-Ezh2 (Cell Signaling, Beverly, MA, USA) and mouse monoclonal anti-Bmi-1 
(Abcam, MA, USA). The secondary antibodies were anti-mouse IgG Alexa Flour 555 and anti-rabbit 
IgG Alexa Flour 488 (Invitrogen, Oregon, USA). Slides were mounted with SlowFade® Gold 
antifade reagent with DAPI (Invitrogen, Oregon, USA) and examined with a conventional 
immunofluorescence microscope (IX71, Olympus, Tokyo, Japan).  The following combinations were 
used: Ezh2 with Bmi-1, Ezh2 with Ki67 and Bmi-1 with Ki67. 
 
Western blotting analysis 
The Western blot analyses were performed as described previously [28]. Rabbit anti-Ezh2, 
mouse anti-Bmi-1, rabbit anti-Mel-18 (Santa Cruz Biotechnologies Inc., Texas, USA) and mouse anti-
beta-actin (Sigma Aldrich, St Louis, USA) antibodies and HRP-labeled anti-rabbit or anti-mouse 
antibodies (NA9340V GE and NA9310V, respectively, GE Healthcare, little Chalfont 
Buckinghamshire, UK) were used for the analyses.  
 
Statistical analysis 
All statistical analyses were done with the SPSS version 11.5 software program. Person`s Chi 
squared test and one-way ANOVA with the Bonferroni’s correction were used to compare the 
different lymphoma subtypes.  Spearman’s and Pearson’s coefficients were used for the correlation 
analyses of Bmi-1, Ezh2 and Ki67. 
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Results 
Expression of Bmi-1 and Ezh2 in normal lymphoid tissues 
 In RLH, the expression of Bmi-1 and Ezh2 was mutually exclusive. Bmi-1 was mainly 
expressed in the mantle zone while Ezh2 was expressed in the germinal center; centroblasts showed 
stronger staining than centrocytes. CD138
+ 
plasma cells were Bmi-1+/- and Ezh2-. CD68
+
 
macrophages were Bmi-1-/Ezh2-. Interfollicular CD3
+
 T, follicular CD4+ T-helper cells and CD56
+
 
NK/T cells were mostly Bmi-1
+
/Ezh2
-
 (Table 1 and Figure S1). The cutaneous CD3+ T-cells were 
Ezh2 negative. In the normal thymus, the cortical thymocytes were mostly Ezh2+/Bmi-1-. In the 
medulla, the pattern was reversed; the dominant population of CD3
+
 cells was Ezh2 -/Bmi-1
+ 
(Table 1 
and Figure S2). The staining intensity for Bmi-1 in both RLH and the thymus was generally weak to 
moderate (Table 1). The normal stratified squamous epithelium covering the tonsils showed nuclear 
staining for Ezh2, mostly in the basal layers while Bmi-1 staining generally showed low expression 
(Figure S3). 
 
High expression of  Bmi-1 and Ezh2 in Hodgkin’s lymphoma and B-cell neoplasms  
In Hodgkin’s lymphomas, the coexpression of both Bmi-1 and Ezh2 was found in the tumor 
cells in 9/10 cases (90%), but was not found in the reactive background cells (Table 1). In B-cell 
neoplasms, the overall expression of Bmi-1 was 84.4%. The staining intensity was generally moderate 
(72 cases) to strong (nine cases). Bmi-1 expression was found in all subtypes, ranging from 58.3% in 
Burkitt’s lymphoma (BL) to 100% in four subtypes: Mantle cell lymphoma (MCL), chronic 
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mucosa associated lymphoid tissue 
(MALT) lymphoma and plasmacytome (PC) (Table 1). MCL showed a moderate staining in more than 
90% of tumor cells in all cases. PC and plasma cell myeloma (PCM) showed a stronger staining 
intensity compared to the weak staining in 20% of normal CD138+ plasma cells (X
2
=8.718, P=0.033). 
In both PCM and PC, the percentage of positive tumor cells was above 80% in 10 cases (Table 1, 
Figures 1 and S1). MALT lymphoma expressed Bmi-1 in 100% of cases. Strong staining was noted in 
7/10 cases (70%), and the percentage of positive tumor cells was more than 90% in all cases.  
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Follicular lymphoma grade 1 and 2 (FLG1-2) expressed Bmi-1 in 73.7% of cases, compared to the 
negative germinal center light zone (Table 1, X
2
=14.246, P=0.003). DLBCL-GCB showed moderate 
to strong staining in 85.7% of cases (Table 1 and Figure 1). The expression in BL, DLBCL-GCB and 
FLG3 showed significant differences compared to the germinal center dark zone (Table 1, X
2
=15.221, 
P=0.002), and the percentage of positive tumor cells was above 70% in 10 cases. No significant 
difference was found between FLG1-2 and follicular lymphoma grade 3 (FLG3) in either the 
percentage or intensity of staining. In addition, no difference was noted between the DLBCL-GCB 
and DLBCL non-GCB subtypes.  
The overall expression of Ezh2 in B-cell neoplasms was 56.9% (Table 1). The expression 
varied among the different subtypes. The highest percentage of positivity was found in BL, FLG3 and 
DLBCL (100%, 87.5% and 85.7%, respectively).  The percentage of positive tumor cells was 
generally greater than 80% in the three entities. FLG3 showed 87.5% positivity versus 57.8% in 
FLG1-2. The strongest staining intensity was seen in DLBCL-GCB, in which 8/14 cases (57.1%) 
showed stronger staining intensity than the germinal center dark zone while the staining in FLG3 was 
comparable to the latter (Table 1 and Figure 1). The difference in the expression of Ezh2 in BL, 
DLBCL-GCB and FLG3 compared to the germinal center dark zone was not significant (X
2
=7.0279, 
P=0.064). FLG1-2 expressed Ezh2 in 57.8% of cases, and the expression was comparable to that of 
the light zone (X
2
=5.836, P=0.054).  In MCL, an enhanced expression of Ezh2 was noted in 66.7% of 
cases, compared to 3.5% of normal mantle zone cells. CLL/SLL expressed Ezh2 in 20% of cases. 
Plasma cell myeloma (PCM) expressed Ezh2 in 14.3% of cases while PC, lymphoplasmacytic 
lymphoma and MALT lymphoma were negative for Ezh2 (Table 1). Plasma cell neoplasms did not 
show any noticeable difference in Ezh2 expression levels compared to normal CD138+ cells 
(X
2
=0.745, P=0.388)  (Table1, Figures 1 and S1).  
 
High expression of Bmi-1 and Ezh2 in T- and NK/T-cell non-Hodgkin’s lymphomas 
The overall expression of Bmi-1 was 84.6% in T- and T/NK-cell lymphomas. Bmi-1 was 
expressed in all subtypes, ranging from 66.7% in adult T-cell leukemia/lymphoma (ATLL) and up to 
100% in three subtypes: angioimmunoblastic T-cell lymphoma (AITL), cutaneous T-cell lymphoma 
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(CTCL) and anaplastic large cell lymphoma (Table 1).  In all of the positive cases, Bmi-1 was 
expressed in more than 80% of the tumor cells. Moderate staining was noted in 37/78 cases (47.4%), 
and strong staining  in 17/78 cases (21.8%), compared to the weaker staining in the normal CD3+, 
CD4+ and CD56+ cells in RLH and skin (Table1, Figures 2, S1 and S2).  
Ezh2 expression was observed in all T- and T/NK-cell lymphoma subtypes, ranging from 
66.7% in AITL to 100% in CTCL (Table 1). A moderate staining intensity in these neoplasms was 
noted, which was in contrast to almost a complete lack of expression of Ezh2 in normal CD3+, CD4+ 
and CD56+ cells in RLH and skin (Figures 2, S1 and S2). Among the positive cases, the highest 
percentage of positive tumor cells was in T-LBL (90%) and the lowest was in CTCL (40%). In mature 
T- and T/NK-cell lymphomas, a significant overexpression of both proteins compared to 
interfollicular, follicular and cutaneous CD3+ T-cells, as well as CD56+ NK- cells, was detected 
(X
2
=13.075, P=0.007 for Bmi-1 and X
2
=38.942, P=0.000 for Ezh2). 
 
Significant differences in  Ezh2, but not Bmi-1 expression between high- and low-grade B-cell 
neoplasms 
High expression levels of Ezh2 were found mainly in the aggressive variants of B-cell 
neoplasms while Bmi-1 was highly expressed in all subtypes with no noticeable difference among 
them (Figure 3A). The Chi squared test for Ezh2 showed a significant difference among the 
subgroups of B-cell lymphomas (X
2
 = 37.561, P= 0.000), and a one-way ANOVA with the Bonferroni 
correction revealed that there were significant differences between the aggressive subtypes (BL, 
DLBCL-GCB, DLBCL non-GCB and FLG3) and the indolent subtypes (FLG1-2, PC, PCM, LPL, 
CLL/SLL and MALT lymphoma) (mean difference = 1.06~2.31, P = 0.000~0.030). This difference 
corresponded to the differences in the Ki67 index (mean difference = 0.56~1.00, P = 0.000~0.018) 
among these subtypes (Table 2). The Chi squared test for Bmi-1 showed a difference in the expression 
among the subtypes of B-cell lymphomas (X
2
 = 99.257, P = 0.000).  However, a one-way ANOVA 
with the Bonferroni correction detected a single statistically significant difference, between BL and 
MALT lymphoma (mean difference = -1.38, P = 0.004) (Table 2).  No statistically significant 
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differences were detected among the subtypes of T/NK-cell lymphomas with regard to the expression 
of Bmi-1, Ezh2 and Ki67 (Figure 3B and Table S3). 
 
Ezh2 expression correlated with the proliferative activity 
The Ki67 labeling index showed a strong positive correlation with Ezh2 expression in B-cell 
neoplasms (correlation coefficient (Co) = 0.983, P = 0.000) and a considerable correlation in T- and 
T/NK-cell lymphomas (Co = 0.629, P = 0.000). This correlation was not detected in the case of Bmi-
1 (Co=-0.224, P=0.121) in B-cell neoplasms, or (Co=-0.251, P=0.146) in T- and T/NK-cell 
lymphomas (Figure 4A). Fluorescent immunohistochemical staining of Ezh2 and Ki67 in DLBCL 
showed that almost all cells strongly co-expressed Ezh2 and Ki67. A low Ki67 proliferation index was 
observed in MALT lymphoma, which closely correlated with a low expression of Ezh2 (Figure 4B, 
white arrowhead). A few cells were stained weakly for Ki67 and Ezh2 (yellow arrowhead). Some 
cells showed intracellular co-localization of Ezh2 and Ki67 (red arrowhead). Fluorescent 
immunohistochemical staining revealed that the expression of Ezh2 closely correlated with that of 
Ki67 in almost all cells in B-cell lymphoma, in accordance with the correlation analysis (Figures 4A 
and B).  
 
Expression of Mel-18 in RLH and malignant lymphomas 
Immunohistochemical staining revealed low expression of Mel-18 in RLH. Double staining 
with CD20 revealed only a few double positive cells in the germinal center and mantle zones. The 
same pattern was detected in the interfollicular areas, and double staining with CD3 revealed a few 
double positive cells. CD138+ plasma cells and CD56+ NK/T cells were both generally negative for 
Mel-18 (Table 3 and Figure 5). The normal stratified squamous epithelium covering the tonsils 
showed nuclear and cytoplasmic staining in both the basal and superficial layers (Figure S3). 
Mel-18 was expressed in 14.7% of B-cell neoplasms. DLBCL-GCB, DLBCL non-GCB, 
FLG1-2, PCM and PC all showed weak expression in 16.7% of cases. MALT lymphoma showed 
weak expression in 10% of cases. In T/NK-cell neoplasms, Mel-18 was expressed in 20% of cases. 
Both NK/T lymphoma and ALCL expressed Mel-18 in 33.4% of cases. T-LBL and ATLL showed 
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expression in 16.7% of cases while PTCL was negative in all cases. The staining intensity was 
typically weak, and the percentage of positive tumor cells was generally below 40% in the positive 
cases. Mel-18 was expressed weakly in 11/ 64 non-Hodgkin’s lymphomas (Table 3 and Figure 5). Co-
expression of Mel-18 and Bmi-1 was observed in 10 lymphoma cases. It is worth mentioning that one 
case of DLBCL-non GCB showed moderate staining for Mel-18 in 80% of tumor cells, and this case 
was Bmi-1 negative.  
 
Expression of Ezh2, Bmi-1 and Mel-18 in hematopoietic cell lines   
 Normal resting PBMCs and CD4
+ 
cells were negative for Ezh2 and Mel-18 while the 
expression of Bmi-1 varied a little; a faint signal was observed in PBMC#1 and normal NK cells. The 
expression of the three proteins was not stable in PBMCs; stimulation of normal T-cells with 
CD3/CD28 immunobeads induced a weak expression of all three proteins (Figure 6C). Human 
mesenchymal stem cells (hMSCs) showed a strong expression of both Bmi-1 and Ezh2 and a weak 
expression of Mel-18. Lymphoma cell lines showed higher levels of both Bmi-1 and Ezh2 proteins 
compared to normal PBMCs. Mel-18 showed weak or no expression in B-cell lymphoma cell lines 
and T/NK lymphoma/leukemia cells compared to the high expression of Bmi-1. HTLV-1 
immortalized cell lines (IWA1, MT4 and MT2) showed enhanced expression of Bmi-1, Mel-18 and 
Ezh2 proteins compared to PBMCs and normal CD4+ cells.  The ratio of Bmi-1/Mel-18 was 
comparable in normal PBMCs and HTLV-I-immortalized cell lines; on the other hand, this ratio  
noticeably increased in malignant lymphoma cell lines (Figures 6A and B). 
Immunofluorescent staining showed that normal resting PBMCs were negative for Ezh2, and 
a small population was weakly positive for Bmi-1. Immunofluorescent staining of several B and 
T/NK- lymphoma cell lines confirmed the higher expression levels of both proteins compared to those 
in normal PBMCs (Figure S4). 
 
Discussion 
The expression profile of Bmi-1 and Ezh2 in normal lymphoid tissues was mutually exclusive. 
Bmi-1 was expressed in the resting cells of the mantle zone, interfollicular T- zone and small 
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percentage of plasma cells while Ezh2 was expressed in the proliferating cells of the germinal center. 
In the thymus, Ezh2 expression predominated in the cortex while Bmi-1 predominated in the 
differentiated cells of the medulla. This is consistent with the findings of previous reports [29-32]. 
Mel-18 expression in RLH was generally low, which is also consistent with previous reports [33].    
The present study showed that Bmi-1 is highly expressed in all subtypes of both B- and T- 
cell lymphomas, including the indolent types: MALT lymphoma, PC, PCM, LPL and CLL/SLL. Bmi-
1 was previously reported to be preferentially expressed in aggressive B-cell lymphoma (DLBCL and 
BL) but not in indolent subtypes (FL and CLL/SLL) [34]. In the case of FL, the present study showed 
that Bmi-1 positivity is highly heterogeneous and dependent on each patient specimen; this might be 
due to differences in the patient populations (Table 1). No significant differences in the expression 
level of Bmi-1 were found in different grades of FL in the present study, suggesting that the 
expression of Bmi-1 does not contribute to the progression from low to high grade FL.  Bmi-1 was 
reported to be one of the genes showing the signature of activated B-cell (ABC) type DLBCL, and 
could be used to distinguish it from the GCB type by a cDNA microarray analysis, and was therefore 
considered to be associated with a poor prognosis [35]. Later reports based on the 
immunohistochemical analyses showed that Bmi-1 expression was not restricted to the ABC type [14]. 
The present study showed that both GCB and non-GCB types expressed Bmi-1 with no significant 
difference noted between the subtypes (Tables 1 and 2), suggesting that the earlier differences might 
have been due to the differences between protein and mRNA expression since they are not always 
consistent. In this study, enhanced expression of Bmi-1 compared to the normal counterpart samples 
was found in some subtypes of lymphomas: BL, DLBCL-GCB, FLG1-3, PC, PCM and T-cell 
lymphomas (P=0.002~0.033). This is consistent with reports that Bmi-1 transgenic mice developed 
lymphoma, and that Bmi-1 is a negative regulator of the INK4a-ARF locus, which encodes tumor 
suppressor proteins p16
Ink4a
, p19
Arf
 and p15
 Ink4b 
[13, 36].  
 Meanwhile, Ezh2 showed a different expression profile in malignant lymphomas. The present 
study showed that Ezh2 expression was significantly stronger in the aggressive types of B-cell 
neoplasms (BL, DLBCL and FLG3) than the indolent subtypes (FLG1-2, SLL, LPL, PC, PCM and 
MALT lymphoma) (P = 0.000~0.030) (Table 2). The Ezh2 positivity in FLG3 was higher than that in 
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FLG1-2. In T/NK-cell lymphomas, Ezh2 showed high expression compared to the negativity 
observed in normal counterpart samples (X
2
=38.942, P=0.000).   However, no significant difference 
among subtypes was noted, which could be explained by the fact that most T/NK-cell lymphomas 
were aggressive with a high Ki67 proliferation index (Table 1). This was supported by the strong 
positive correlation between Ki67 and the Ezh2 expression in B-cell lymphoma (Co = 0.983, 
P=0.000) and the considerable correlation in T-cell lymphoma (Co = 0.629, P = 0.000) (Figure 4A). 
This is consistent with previous reports that Ezh2 overexpression is associated with increased 
proliferation, metastasis and poor prognosis in breast, prostate and stomach cancers [18-20]. These 
findings suggest that Ezh2 overexpression is also associated with the proliferation and aggressiveness 
in lymphoma. 
It has been reported that Bmi-1 and other members of PRC1 function downstream of PRC2 [7, 
8]. However, the present study showed that there are different expression patterns of Bmi-1 and Ezh2. 
These proteins do not always co-localize in RLH and malignant lymphomas indicating that, at least in 
some situations, they function independently. This is supported by evidence that there are genes 
targeted by PRC2 that lack the product of PRC1 catalysis (H2AK119ub), and genes targeted by PRC1 
in the absence of PRC2 [37, 38]. 
McCabe et al reported that GSK126 is a potent and highly selective inhibitor of Ezh2 
methyltransferase activity that decreased the global H3K27me3 level and induced pharmacological 
inhibition of the proliferation in Ezh2 mutant lymphoma. GSK126 also reduced the H3K27me3 levels 
in wild-type DLBCL cell lines [39].  In view of the low expression of Ezh2 in normal resting 
populations, selective pharmacological intervention to inhibit Ezh2 activity in both wild type and 
mutant lymphomas is a promising approach that warrants further research. 
    Mel-18 expression was previously reported in several normal adult tissues [15-17]. In RLH, 
we found that few cells expressed Mel-18 with moderate intensity while some populations expressed 
Bmi-1 with weak to moderate intensity, especially in the mantle zone. In B- and T/NK-cell neoplasms, 
Bmi-1 expression was found in 158/187 (84.5%) of cases, and the staining intensity was mostly 
moderate (109 cases) to strong (26 cases) while Mel-18 was expressed weakly in 11/64 cases (17.1 %) 
of B- and T/NK cell neoplasms (Tables 1 and 3). The Western blot analysis revealed that both B- and 
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T/NK-cell lymphoma cell lines showed weak or no expression of Mel-18, in contrast to their 
moderate/strong expression of Bmi-1 while normal PBMCs were negative for Mel-18 and 
negative/faintly positive for Bmi-1 (Figure 6). The ratio of Bmi-1/Mel-18 (PRC1.4/PRC1.2) was 
comparable in normal PBMCs and HTLV-I-immortalized cell lines, and increased noticeably in 
malignant lymphoma cell lines. Together, these data suggest that the regulation of PRC1 in the normal 
lymphoid tissue is in favor of PRC1.4, rather than PRC1.2, and that the difference increases with the 
development of malignancy. Only PRC1.2 and PRC1.4 complexes have been shown to accumulate in 
H3K27me3-rich regions; they induce chromatin compaction and gene silencing in different targets, 
and are suggested to play a central role in PRC1 function [6]. The altered expression state may induce 
changes in the downstream gene targeting and expression in lymphomas. 
  In conclusion, B-and T/NK- cell neoplasms show high expression of both Bmi-1 and Ezh2 
while maintaining low expression of Mel-18. The regulation of PRC1.2 and PRC1.4 shifts more 
towards PRC1.4 dominance in the neoplastic state.  The coexpression of Bmi-1 and Ezh2 is a 
characteristic of the aggressive variants of these lymphomas. Ezh2 correlates with tumor proliferation, 
and can be used to distinguish proliferative/aggressive lymphoma variants from indolent ones and 
normal resting cell populations. A detailed understanding of the precise role(s) of these proteins in 
lymphomagenesis is still lacking. However, correlation between the expression status of Ezh2 and the 
Bmi-1/Mel-18 ratio with the patients’ prognosis may provide a useful method for the pathological 
evaluation of lymphomas in the future. 
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Titles and legends to figures 
Fig. 1. Immunohistochemical staining of Bmi-1 and Ezh2 in reactive lymphoid hyperplasia 
and B-cell neoplasms 
 (a) Bmi-1 expression was detected mainly in the mantle zone (MZ) while the germinal center 
(GC) was negative. (b) Ezh2 expression was detected in the GC while the MZ was negative (Insets 
show a higher magnification of the GC). (c) and (d) DLBCL-GCB-type was strongly positive for 
Bmi-1 and Ezh2, respectively. (e) and (f) Follicular lymphoma grade 3 was strongly positive for 
Bmi-1 and Ezh2, respectively. (g) and (h) Plasma cell myeloma was strongly positive for Bmi-1 
and negative for Ezh2, respectively (a and b: Magnification x 200, inset x 400 and c to h:  
Magnification x400). 
 
Fig. 2. Immunohistochemical staining of Bmi-1 and Ezh2 in T- and NK-cell lymphomas 
 (a) and (b) ATLL was strongly positive for Bmi-1 and Ezh2, respectively. (c) and (d) NK/T 
lymphoma was strongly positive for Bmi-1 and Ezh2, respectively. (e) and (f) T-LBL was strongly 
positive for Bmi-1 and Ezh2, respectively (Magnification x400). 
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Fig. 3. Expression profiles of Bmi-1 and Ezh2 in malignant lymphoma subtypes and normal 
control cells 
 (a) B-cell neoplasms. (b) T/NK-cell lymphomas. MZ: Mantle zone, GC dark: Germinal center dark 
zone, GC light: Germinal center light zone, Norm PC: Normal plasma cells, BL: Burkitt’s 
lymphoma, DLBCLGC: Diffuse large cell B-cell lymphoma germinal center type, DLBCLNG: 
Diffuse large B-cell lymphoma non-germinal center type, FLG3: Follicular lymphoma grade 3, 
FLG1-2: Follicular lymphoma grade 1 and 2, MCL: Mantle cell lymphoma, CLL/SLL: Chronic 
lymphocytic leukemia/small lymphocytic lymphoma, PCM: Plasma cell myeloma, PC: 
Plasmacytoma, LPL: Lymphoplasmacytic lymphoma, MALT: Mucosa-associated lymphoid tissue 
lymphoma, Norm NK/T: Normal natural killer T-cell, IF: Interfollicular, T-LBL: T-cell 
lymphoblastic lymphoma, ATLL: Adult T-cell leukemia/lymphoma, ALCL: Anaplastic large cell 
lymphoma, PTCL: Peripheral T-cell lymphoma, NK/T: Natural killer/T-cell lymphoma, CTCL: 
Cutaneous T-cell lymphoma and AITL: Angioimmunoblastic T-cell lymphoma. 
 
Fig. 4. The correlation between Ezh2 and Ki67 expression, and between Bmi-1 and Ki67 
expression based on the percentage of positive cells in both B- and T/NK-cell lymphomas 
 (A): (a) and (c) B-cell lymphomas. (b) and (d) T/NK-cell lymphomas. Co is the Pearson’s 
correlation coefficient (The correlation was considered significant at the 0.01 level). (a) and (b) 
The correlation between Ki67 and Ezh2. (c) and (d) The correlation between Ki67 and Bmi-1. (B) 
Double fluorescent immunohistochemical staining of Ezh2 and Ki67 in DLBCL and MALT 
lymphoma patient specimens: (a) A high percentage of Ki67 (+) cells was found in DLBCL. (b) 
High expression of Ezh2 was found in the same case. (c) DAPI staining, (d) Merged Ezh2 and 
Ki67 staining showed coexpression in the same cells. (e) A low percentage of Ki67 (+) cells was 
found in MALT lymphoma. (f) A few cells expressed Ezh2 in the same case. (g) DAPI staining, (h) 
Merged Ezh2 and Ki67 staining. The yellow arrowheads show single positive for Ki67 and 
negative for Ezh2; many cells co-expressed Ki67 and Ezh2 (white arrowheads). The red 
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arrowheads show intracellular co-localization of Ezh2 and Ki67 (Magnification x400, Ezh2: red, 
Ki67: green). 
 
Fig. 5. Expression of Mel-18 in normal tonsil and malignant lymphomas 
 (a) Few cells expressed Mel-18 in the germinal center and interfollicular zone of normal tonsils 
while the stratified squamous epithelial cells were positive (Inset from the germinal center showing 
one centroblast with moderate staining intensity for Mel-18) (b) Mucosa-associated lymphoid 
tissue (MALT) lymphoma showed a few cells with moderate staining intensity. (c) Diffuse large B-
cell lymphoma showed a few cells weakly expressing Mel-18 (d) NK/T cell lymphoma showed a 
few cells weakly expressing Mel-18 (a: Magnification x100, inset: x400,  b to d: Magnification 
x400). 
 
Fig. 6. Results of the Western blot analyses of Bmi-1, Ezh2 and Mel-18 expression in 
malignant lymphoma cell lines and normal control cells 
 (A) Both Bmi-1 and Ezh2 were expressed in most B-cell lymphoma lines; however, Ezh2 showed 
a stronger signal in the more aggressive lymphoma lines. Mel-18 was negative in most B-cell lines 
(B) Both Bmi-1 and Ezh2 were expressed in most T-cell lymphoma lines. Mel-18 was 
weakly/faintly positive in ATLL leukemic cell lines (ED40515 and ATL55T). This was in contrast 
to HTLV-I immortalized cell lines (IWA1, MT4 and MT2), which showed an expression level 
comparable to that of Bmi-1. (C) Normal PBMCs#1 and normal NK cells showed a faint signal for 
Bmi-1 while they were negative for Ezh2 and Mel-18. Activated T-cells showed a faint expression 
of all three proteins. PBMCs#1 to #4: Peripheral blood mononuclear cells (PBMCs) from four 
healthy individuals, Activate T: T-cells activated with a CD3/CD28 cell expander and Norm NK: 
Normal natural killer (NK) cells.  
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Table 1. Ezh2 and Bmi-1 expression and Ki67 labeling index in different subtypes of lymphoma and normal control 
 
Malignant lymphoma 
and normal control 
Ezh2 Bmi-1 Ki67 
- + ++ +++ positive/ 
 Total  
Positivity 
% 
- + ++ +++ positive / 
Total  
Positivity 
% 
High/ 
Total 
High 
% 
HD 1 4 5 0 9/10 90% 1 2 7 0 9/10 90% ND ND 
BL 0 0 10 2 12/12 100 % 5 3 4 0 7/12 58.3% 12/12 100% 
DLBCL-GCB 2 2 2 8 12/14 85.7 % 2 1 9 2 12/14 85.7 % 13/14 92.8% 
DLBCL non GCB 2 2 9 1 12/14 85.7% 1 3 10 0 13/14 92.9% 14/14 100% 
FLG3 1 0 7 0 7/8 87.5% 2 2 4 0 6/8 75% 8/8 100% 
MCL 3 4 2 0 6/9 66.7% 0 0 9 0 9/9 100% 4/9 44.4% 
FLG1- 2 8 3 8 0 11/19 57.8 % 5 1 10 3 14/19 73.7 % 3/19 15.7% 
CLL/SLL 4 0 1 0 1/5 20 % 0 0 5 0 5/5 100% 1/5 20% 
PCM 6 0 1 0 1/7 14.3 % 1 1 5 0 6/7 85.7 % 2/7 28.6% 
PC 6 0 0 0 0/6 0% 0 0 5 1 6/6 100% 1/6 16.7% 
LPL 5 0 0 0 0/5 0% 1 0 4 0 4/5 80% 0/5 0% 
MALT lymphoma 10 0 0 0 0/10 0 % 0 0 3 7 10/10 100 % 1/10 10% 
B-cell neoplasms 47 11 40 11 62/109 56.9% 17 11 72 9 92/109 84.4% 59/109 54.1% 
T-LBL 1 1 8 2 11/12 91.7 % 2 0 3 7 10/12 83.3 % 11/12 91.7% 
ATLL 2 6 8 2 16/18 88.9% 6 2 7 3 12/18 66.7% 15/18 83.3% 
ALCL 1 4 4 0 8/9 88.9% 0 0 9 0 9/9 100% 9/9 100% 
PTCL 4 4 12 0 16/20  80 % 3 2 10 5 17/20 85 % 17/20 85% 
NK/T 2 2 6 0 8/10 80% 1 5 2 2 9/10 90% 9/10 90% 
AITL 2 0 4 0 4/6 66.7 % 0 1 3 2 6/6 100 % 6/6 100% 
CTCL 0 0 3 0 3/3 100% 0 0 3 0 3/3 100% 3/3 100% 
T- and NK-cell neoplasms 12 17 45 4 66/78 84.6% 12 10 37 17 66/78 84.6% 70/78 89.7% 
RLH               
 Mantle zone 386 10 4 0 14/400 3.5% 21 300 70 9 379/400 94.8% 10/400 2.5% 
Germinal centre dark zone 4 110 80 6 196/200 98% 187 10 3 0 13/200 6.5% 192/200 96% 
Germinal centre light zone 109 70 20 1 91/200 45.5% 183 12 5 0 17/200 8.5% 105/200 52.5% 
 CD 138 + plasma cells 190 7 3 0 10/200 5% 160 35 5 0 40/200 20% 0/200 0% 
 Interfollicular CD3+  cells 180 15 5 0 20/400 5% 56 250 80 14 354/400 88.5% 6/400 1.5% 
 CD56 + NK/T cells 192 8 0 0 8/200 4% 50 116 30 4 150/200 75% 7/200 3.5% 
Follicular CD4+ T-helper cells 186 14 0 0 14/200 7% 31 140 25 4 169/200 84.5% 4/200 2% 
Normal thymus:               
Cortical CD3 + T cells  172 60 140 28 228/400 57% 340 30 22 8 60/400 15% 200/400 50% 
Medullary CD3 + T cells  329 30 30 11 71/400 17.8% 140 160 75 25 260/400 65% 16/400 4% 
Positivity includes (+), (++) and (+++). HD: Hodgkin lymphoma, BL: Burkitt lymphoma, DLBCL-GCB: Diffuse large cell B cell 
lymphoma germinal centre type, DLBCL non GCB: Diffuse large B- cell lymphoma non germinal centre type, FLG3: Follicular 
lymphoma grade3, FLG1-2: Follicular lymphoma grade 1-2, MCL: Mantle cell lymphoma, CLL/SLL: Chronic lymphocytic 
leukemia/small lymphocytic lymphoma, PCM: Plasma cell myeloma, PC: Plasmacytoma, LPL: Lymphoplasmacytic lymphoma, 
MALT: Mucosa associated lymphoid tissue, T-LBL: T-cell lymphoblastic lymphoma, ATLL: Adult T-cell leukemia/lymphoma, 
ALCL: Anaplastic large cell lymphoma, , PTCL: Peripheral T-cell lymphoma, NK/T: Natural killer/T-cell lymphoma, AITL: 
Angioimmunoblastic T-cell lymphoma, CTCL: Cutaneous T-cell lymphoma, RLH : Reactive lymphoid hyperplasia. Data from 
RLH and thymus are based on cell count. 
 
 
 
 
 
 
 
 
 
 
Table
Table 2. Difference in expression of Bmi-1, Ezh2 and Ki67 among different subtypes of B-cell non Hodgkin lymphoma 
Protein  BL DLBCL-GCB DLBCL Non-GCB   FL G3 FL G1-2 
Bmi-1 DLBCL-GCB -0.87 
P=0.327 
    
DLBCL non-GCB - 0.73 
P=1.000 
0.14 
P=1.000 
   
FL G3 
 
-0.33 
P=1.000 
0.54 
P=1.000 
0.39 
P=1.000 
  
FL G1-2 
 
-0.66 
P=1.000 
0.21 
P=1.000 
0.06 
P=1.000 
-0.33 
P=1.000 
 
MCL 
 
-1.08 
P=0.128 
-0.21 
P=1.000 
- 0.36 
P=1.000 
- 0.75 
P=1.000 
- 0.42 
P=1.000 
PCM 
 
-0.65 
P=1.000 
0.21 
P=1.000 
0.07 
P=1.000 
- 0.32 
P=1.000 
0.01 
P=1.000 
PC 
 
-1.25 
P=0.108 
- 0.38 
P=1.000 
- 0.52 
P=1.000 
- 0.92 
P=1.000 
- 0.59 
P=1.000 
LPL 
 
-0.68 
P=1.000 
0.19 
P=1.000 
0.04 
P=1.000 
- 0.35 
P=1.000 
- 0.02 
P=1.000 
MALT 
 
-1.38* 
P=0.004 
- 0.51 
P=1.000 
- 0.66 
P=1.000 
-1.05 
P=1.000 
- 0.72 
P=1.000 
CLL/SLL 
 
-1.08 
P=0.607 
- 0.21 
P=1.000 
-0.36 
P=1.000 
-0.75 
P=1.000 
-0.42 
P=1.000 
Ezh2 DLBCL-GCB -0.14 
P=1.000 
    
DLBCL non-GCB 0.52 
P=1.000 
0.66 
P=1.000 
   
FL G3 
 
0.42 
P=1.000 
0.56 
P=1.000 
-0.11 
P=1.000 
  
FL G1-2 1.11* 
P=0.007 
1.25* 
P=0.001 
0.59 
P=1.000 
0.69 
P=1.000 
 
MCL 
 
1.28* 
P=0.011 
1.42* 
P=0.002 
0.75 
P=1.000 
0.86 
P=1.000 
0.17 
P=1.000 
PCM 
 
1.88* 
P=0.000 
2.02* 
P=0.000 
1.36* 
P=0.009 
1.46* 
P=0.015 
0.77 
P=1.000 
PC 
 
2.17* 
P=0.000 
2.31* 
P=0.000 
1.64* 
P=0.001 
1.75* 
P=0.002 
1.06 
P=0.191 
LPL 
 
2.17* 
P=0.000 
2.31* 
P=0.000 
1.64* 
P=0.003 
1.75* 
P=0.005 
1.06 
P=0.346 
MALT 
 
2.17* 
P=0.000 
2.31* 
P=0.000 
1.64* 
P=0.000 
1.75* 
P=0.000 
1.06 
P=0.030 
CLL/SLL 
 
1.77* 
P=0.001 
1.91* 
P=0.000 
1.24 
P=0.105 
1.35 
P=0.113 
0.66 
P=1.000 
Ki67 DLBCL-GCB 0.00 
P=1.000 
    
DLBCL non-GCB 0.00 
P=1.000 
0.00 
P=1.000 
   
FL G3 
 
0.00 
P=1.000 
0.00 
P=1.000 
0.00 
P=1.000 
  
FL G1-2 
 
0.80* 
P=0.000 
0.80* 
P=0.000 
0.80* 
P=0.000 
0.80* 
P=0.000 
 
MCL 
 
0.56* 
P=0.005 
0.56* 
P=0.004 
0.56* 
P=0.003 
0.56* 
P=0.018 
- 0.24 
P=1.000 
PCM 
 
0.71* 
P=0.000 
0.71* 
P=0.000 
0.71* 
P=0.000 
0.71* 
P=0.001 
-0.09 
P=1.000 
PC 
 
0.80* 
P=0.000 
0.80* 
P=0.000 
0.80* 
P=0.000 
0.80* 
P=0.001 
0.00 
P=1.000 
LPL 
 
1.00* 
P=0.000 
1.00* 
P=0.000 
1.00* 
P=0.000 
1.00* 
P=0.000 
0.20 
P=1.000 
MALT 
 
0.90* 
P=0.000 
0.90* 
P=0.000 
0.90* 
P=0.000 
0.90* 
P=0.000 
0.10 
P=1.000 
CLL/SLL 
 
0.80* 
P=0.000 
0.80* 
P=0.000 
0.80* 
P=0.000 
0.80* 
P=0.001 
0.00 
P=1.000 
One way ANOVA with Bonferroni correction, upper panel is the mean difference, * and bold font indicate significant values (P <0.05 
level). BL: Burkitt    lymphoma, DLBCL (GCB): Diffuse large cell B-cell lymphoma germinal centre type, DLBCL non GCB: Diffuse 
large B- cell lymphoma non germinal centre type, FLG3: Follicular lymphoma grade3, FLG1,2: Follicular lymphoma grade 1,2, MCL: 
Mantle cell lymphoma, CLL/SLL: Chronic lymphocytic leukaemia/small lymphocytic lymphoma, PCM: Plasma cell myeloma, PC: 
Plasmacytoma, LPL: Lymphoplasmacytic lymphoma, MALT: Mucosa associated lymphoid tissue 
 
 
 
 
 
      Table 3. Expression of Mel-18 in RLH and malignant lymphomas 
 
Positivity includes (-), (+), (++) and (+++). DLBCL-GCB: Diffuse large cell B cell lymphoma germinal centre type, 
DLBCL non GCB: Diffuse large B- cell lymphoma non germinal centre type, FLG1-2: Follicular lymphoma grade 1-
2, PCM: Plasma cell myeloma, PC: Plasmacytoma, MALT: Mucosa associated lymphoid tissue, T-LBL: T-cell 
lymphoblastic lymphoma, ATLL: Adult T-cell leukemia/ lymphoma, ALCL: Anaplastic large cell lymphoma, , 
PTCL: Peripheral T-cell lymphoma, NK/T: Natural killer/T-cell lymphoma, RLH : Reactive lymphoid hyperplasia. 
Data from RLH are based on cell count. 
 
 
 
 
 
 
 
Malignant lymphoma    Mel-18 Positive/ Positivity 
and  normal control - + ++ +++ Total % 
DLBCL-GCB 5 1 0 0  1/6 16.7% 
DLBCL non-GCB 5 0 1 0  1/6 16.7% 
FLG1-2 5 1 0 0  1/6 16.7% 
PCM and PC 5 1 0 0  1/6 16.7% 
MALT lymphoma 9 1 0 0  1/10 10% 
          B-cell neoplasms 29 4 1 0 5/34 14.7% 
T-LBL 5 1 0 0 1/6 16.7% 
ATLL 5 1 0 0 1/6 16.7% 
PTCL 6 0 0 0 0/6 0% 
NK/T lymphoma 4 2 0 0 2/6 33.4% 
ALCL 4 2 0 0 2/6 33.4% 
      T/NK-cell neoplasms 19 5 0 0  6/30 20% 
RLH       
Mantle zone 390 0 10 0 10/400 2.5% 
Germinal centre dark zone 184 0 14 0 14/200 7% 
Germinal centre light zone 195 0 5 0 2/200 2.5% 
 CD 138 + plasma cells 196 0 4 0 2/200 2% 
 Interfollicular CD3 +  cells 192 0 8 0 8/200 4% 
 CD56 + NK/T cells 197 0 4 0 4/200 2% 
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